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Mutation of the E6-AP Ubiquitin Ligase Reduces
Nuclear Inclusion Frequency While Accelerating
Polyglutamine-Induced Pathology in SCA1 Mice
the spinocerebellar ataxias types 2, 3, 6, and 7 (Wells
and Warren, 1998).
The mechanism by which the mutation in SCA1 leads
to neuronal degeneration remains elusive. Mice with a
targeted deletion in the Sca1 gene demonstrate learning
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deficits and decreased hippocampal paired±pulse facili-1Program in Cell and Molecular Biology
tation, but show none of the symptoms of the human2Department of Pediatrics
disease (Matilla et al., 1998). These findings indicate3Department of Pathology
that SCA1 is not caused by loss of function of ataxin-1.4Department of Molecular and Human Genetics
Studies in transgenic mice support a dominant, toxic5Howard Hughes Medical Institute
gain of function model. Overexpression of a mutantBaylor College of Medicine
SCA1 allele with 82 glutamines using the regulatory se-Houston, Texas 77030
quences of the Purkinje cell±specific promoter (Pcp2)6Department of Biochemistry
causes progressive ataxia and Purkinje cell degenera-Technion-Israel Institute of Technology
tion (Burright et al., 1995). The pathological changes inHaifa 31096
one line, termed B05, have been well characterizedIsrael
(Clark et al., 1997). In these mice the transgene expres-7Departments of Laboratory Medicine and Pathology
sion is first detectable by Northern analysis at postnataland Institute of Human Genetics
day 10 (P10). The cerebella and Purkinje cell dendriticUniversity of Minnesota
arborization develop normally and the mice have noMinneapolis, Minnesota 55455
developmental abnormalities. The earliest histological
changes begin at P25 with the appearance of cyto-
plasmic vacuoles in the Purkinje cells. At five weeks,Summary
the mice begin to show thinning of the Purkinje cell
dendritic branches and spines. Around this same time,Mutant ataxin-1, the expanded polyglutamine protein
the B05 mice show impaired performance on the rotatingcausing spinocerebellar ataxia type 1 (SCA1), aggre-
rod apparatus. At 12 weeks the molecular layer of cere-gates in ubiquitin-positive nuclear inclusions (NI) that
bellar cortex shrinks and heterotopic Purkinje cells ap-alter proteasome distribution in affected SCA1 patient
pear. The animals develop an ataxic gait between 12neurons. Here, we observed that ataxin-1 is degraded
and 14 weeks of age; severe Purkinje cell pathology andby the ubiquitin-proteasome pathway. While ataxin-1
neuronal death are evident at 6 months.[2Q] and mutant ataxin-1 [92Q] are polyubiquitinated
Immunolocalization studies demonstrate that mutantequally well in vitro, the mutant form is three times
ataxin-1 aggregates in a single nuclear inclusion in themore resistant to degradation. Inhibiting proteasomal
Purkinje cells of SCA1 transgenic mice and affecteddegradation promotes ataxin-1 aggregation in trans-
neurons in SCA1 patients (Skinner et al., 1997). In mice,fected cells. And in mice, Purkinje cells that express
the NI formation is progressive as the percentage ofmutant ataxin-1 but not a ubiquitin-protein ligase have
Purkinje cells with inclusions increases from 25% at 6significantly fewer NIs. Nonetheless, the Purkinje cell
weeks to 90% at 12 weeks of age (Skinner et al., 1997).pathology is markedly worse than that of SCA1 mice.
Before NI formation the mutant protein is still relativelyTaken together, NIs are not necessary to induce neu-
insoluble (Burright et al., 1995). Even the most extremerodegeneration, but impaired proteasomal degrada-
techniques of homogenization, lysis, and sample prepa-
tion of mutant ataxin-1 may contribute to SCA1 patho-
ration allow only a small fraction of the mutant protein
genesis. expressed in the cerebellum to be seen by SDS-PAGE
analysis.
Nuclear inclusions also appear in neurons affected by
Introduction HD, SCA3, SCA7, SMBA, and DRPLA (Davies et al., 1997;
DiFiglia et al., 1997; Paulson et al., 1997; Hayashi et al.,
SCA1 is characterized by ataxia, progressive motor de- 1998; Holmberg et al., 1998; Li et al., 1998 ). Immunohis-
terioration, and loss of cerebellar Purkinje cells and tochemical examination of patient tissue from all of
brainstem neurons. With typical midlife onset, the dis- these diseases showed the NI to contain ubiquitin (re-
ease progresses until death 10 to 15 years later (Zoghbi viewed in Paulson, 1999). In fact, the presence of ubiqui-
et al., 1988). The SCA1 gene was identified in 1993 and tin-positive deposits is a hallmark of many neurode-
the mutation demonstrated to be an expansion of a generative disorders, including Alzheimer's disease,
translated CAG repeat (Orr et al., 1993). Seven other Parkinson's disease, amyotrophic lateral sclerosis, and
disorders share this molecular basis of disease: spino- the prion disorders (Alves-Rodrigues et al., 1998). How
bulbar muscular atrophy (SBMA), Hunington's disease these deposits form and what role they play in pathogen-
(HD), dentatorubral pallidoluysian atrophy (DRPLA), and esis are hotly debated topics (Alves-Rodrigues et al.,
1998; Klement et al., 1998; Saudou et al., 1998; Sisodia,
1998; Perutz, 1999).8 To whom correspondence should be addressed (e-mail: hzoghbi@
bcm.tmc.edu). That the NIs in SCA1 are ubiquitin positive raises the
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possibility that the proteolytic pathway in these neurons E6-AP has a unique expression pattern. Due to tissue-
might be altered (Cummings et al., 1998). Most proteins specific imprinting, the paternal allele is silenced in cere-
destined for degradation undergo covalent conjugation bellar Purkinje cells and hippocampal neurons (Albrecht
with multiple ubiquitin molecules in a multistep mecha- et al., 1997). Interestingly, maternal E6-AP deficiency
nism involving several enzymes (reviewed in Schwartz causes the human genetic disorder Angelman syndrome
and Ciechanover, 1999). The first step involves the acti- (AS) (Jiang et al., 1999). AS is a nondegenerative devel-
vation of ubiquitin by the ubiquitin-activating enzyme opmental disorder characterized by mental retardation,
(E1). The activated ubiquitin is then transferred to one speech impairment, hyperactivity, seizures, ataxia, and
of many ubiquitin-conjugating enzymes (UBCs or E2). inappropriate laughter (Williams et al., 1995). Mice with
The E2 subsequently transfers the ubiquitin directly to a maternal deficiency of E6-AP (Ube3a(m2/p1)) have phe-
the target substrate or to a substrate-specific ubiquitin notypes analogous to human AS, including learning defi-
ligase (E3). A lysine in the first ubiquitin moiety then cits, impaired performance on the rotating rod, and in-
becomes an acceptor for additional ubiquitin molecules ducible seizures (Jiang et al., 1998). Despite these
in successive reactions, thereby creating a polyubiquitin abnormalities, the deficient animals have no detectable
chain. This chain then acts as a molecular flag, targeting developmental nor degenerative histological abnormali-
proteins for ATP-dependent hydrolysis by the 26S pro- ties of the brain (Jiang et al., 1998). Given the role E6-
teasome, a multicatalytic proteinase composed of a 20S AP plays in the UPP and its unique expression pattern
proteasome functional core and a 19S cap-modulator, especially in Purkinje cells, we reasoned that this mouse
also termed PA700 (Coux et al., 1996). The 19S regula- model would provide an opportunity to investigate the
tory complex is known to activate the catalytic core and effects of a compromised ubiquitin-proteasome path-
is believed to be involved in not only the recognition way on the polyglutamine-induced pathology in SCA1
of ubiquitinated proteins but also their unfolding and transgenic mice.
presentation to the 20S core (Baumeister et al., 1998; In this study we examined the role of the ubiquitin-
Glickman et al., 1999). The unfolding of substrates prior proteasome pathway in SCA1 pathogenesis and demon-
to hydrolysis may also require the activity of a diverse strate that ataxin-1 is polyubiquitinated and can be de-
class of highly conserved proteins known as molecular graded by the ubiquitin-proteasome pathway, and that
chaperones or heat shock proteins (Lee et al., 1996; a genetic perturbation of the ubiquitin pathway leads
Rechsteiner, 1998). to an accelerated polyglutamine-induced phenotype in
Recently we demonstrated that various components SCA1 transgenic mice.
of the 26S proteasome as well as molecular chaperones
are redistributed to the sites of ataxin-1 aggregation in
ResultsSCA1 patient tissue and transgenic mice (Cummings et
al., 1998). These findings inspired the hypothesis that
Proteasome Inhibition Increasesthe expansion of the polyglutamine tract alters the con-
Ataxin-1 Aggregationformation of ataxin-1, causing it to misfold. These mis-
Full-length mutant ataxin-1 [82Q] readily aggregates infolded proteins are targeted for degradation by the ubi-
numerous ubiqutin-positive subnuclear structures whenquitin-proteasome pathway (UPP). Expanded ataxin-1
overexpressed in tissue culture cells, and these aggre-could adopt an array of energetically stable structures
gates alter the staining pattern of the 20S proteasomethat resist unfolding and impede proteasomal degrada-
(Skinner et al., 1997; Cummings et al., 1998). The protea-tion. If the capacity of the proteasome is exceeded, NIs
some's abnormal distribution suggests that it is tar-develop as the disease advances. Proteasome redistri-
geting the inclusions in an attempt to degrade the aggre-bution to the NI may contribute to disease progression
gated protein. We therefore examined the effect ofby disturbing proteolysis and subsequent vital cellular
proteasome inhibitors on the aggregation of GFP-functions.
ataxin-1 [82Q] in transfected HeLa cells. The proteaseGiven the possible role of the ubiquitin-proteasome
inhibitor clasto-Lactacystin b-lactone specifically pre-pathway in SCA1, we reasoned that a cross between
vents proteasomal degradation by reacting with the pro-SCA1 transgenic mice and mice with a genetic perturba-
posed active site nucleophile in the 20S catalytic coretion in the UPP may provide insight into SCA1 pathogen-
of the proteasome (Fenteany et al., 1995; Dick et al.,esis. Jiang et al. have recently generated mice with a
1996). b-lactone affects neither cysteine nor serine pro-targeted deletion in the gene encoding an E3-ubiquitin
teases, and it does not inhibit lysosomal degradationligase, Ube3a (Jiang et al., 1998). The Ube3a gene prod-
(Fenteany et al., 1995). Proteasome inhibition for 8 hr byuct, known as E6-associated protein (E6-AP), is a mem-
b-lactone had a dramatic effect on ataxin-1 aggregation.ber of a class of E3s termed the HECT (homologous to
Whereas mock-treated cells had nuclear aggregates inE6-AP C terminus) domain family that form thiol esters
71% of the transfected cells, b-lactone treatment raisedwith ubiquitin and act as the proximal donor in target
the percentage of aggregate-containing cells to 97%ubiquitination (Scheffner et al., 1993; Huibregtse et al.,
(Figures 1A and 1B, SEM # 3%). Moreover, the number1995; Scheffner et al., 1995). E6-AP is the best-charac-
of cells containing the large aggregates was also dra-terized member of this family and is known to be impor-
matically increased compared to mock controls. Only atant for the ubiquitination and degradation of p53 in
small number of treated cells had a diffuse staining pat-conjunction with an ancillary protein, the human papillo-
tern or contained micropunctate structures. A similarmavirus E6 oncoprotein (Huibregtse et al., 1993; Scheff-
ner et al., 1993, 1995; Talis et al., 1998). effect for all constructs was seen with the less potent
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Figure 1. Inhibition of the Proteasome Leads
to Increased Ataxin-1 Aggregation
HeLa cells transfected with GFP-ataxin-1
[82Q] were incubated with or without b-lac-
tone. DMSO-treated control cells show dif-
fuse nuclear staining with several nuclear ag-
gregates (A). Inhibiting the proteasome,
however, promotes aggregation of ataxin-1
(B). Subcellular localization of 20S protea-
some (red) and ataxin-1 [92Q] (green) in HeLa
cells. Examination of the proteasome distri-
bution in nontransfected cells shows diffuse
nuclear staining with occasional large foci in
b-lactone nontreated (C) and treated (D) pop-
ulations. This demonstrates that proteasome
inhibition does not cause an altered subcellu-
lar redistribution of the 20S core. Only in
transfected cells does the distribution of the
proteasome coincide with ataxin-1 aggre-
gates (merge, yellow); the larger aggregates
show a stronger signal.
and less specific proteasome inhibitor, MG132 (CBZ- sulfoxide (DMSO) control. As described above, overex-
pression of ataxin-1 leads to its aggregation in HeLaLLLAL) (data not shown). There was no significant differ-
cells; upon extraction, either in solution or in situ, aence between DMSO- (carrier control) and non-DMSO-
significant amount of the mutant protein is found in thetreated cells, confirming that DMSO treatment alone
detergent-insoluble fraction of the cell (Skinner et al.,does not affect ataxin-1 distribution (67% aggregates
1997). Cell lysates were, therefore, separated into deter-untreated, SEM 5 3.6%). Therefore, proteasome inhibi-
gent-insoluble and soluble fractions to investigate thetor treatment led to an increase in both frequency and
steady-state levels of the two forms of the protein. Im-size of nuclear aggregates. This enhancement is most
munoblots were probed with either ataxin-1 antibody orlikely due to the increased nuclear concentration of mis-
a monoclonal antisera to the Xpress-tagged epitope.folded proteins, which are not being properly degraded.
With cell equivalents loaded per lane, it is clear thatTo show that the b-lactone effect on ataxin-1 aggrega-
b-lactone treatment led to a marked accumulation oftion was not caused by a general aggregation of ubiquiti-
the detergent-insoluble form of ataxin-1, suggesting itsnated proteins or an abnormal distribution of the protea-
degradation is via the proteasome pathway (Figure 2A,some, ataxin-1 [92Q] transfected cells were costained
lanes 1±3). Increasing the protein concentration 3-fold,for ataxin-1 and the 20S proteasome (Figures 1C and
a high molecular weight smear punctuated by discrete1D). In the nontransfected cells, the 20S proteasome had
bands is evident (Figure 2A, lanes 5±6). Interestingly,an identical distribution for both mock- and b-lactone-
the levels of the detergent-soluble form of ataxin-1 ap-treated populations. Likewise in the transfected cells,
peared unchanged in the presence of b-lactone (Figurethere was no difference in the staining pattern of the
2B, lanes 1±3), and the higher molecular weight smear20S core between mock and treated cells except that
was never seen in the overloaded detergent-solublethe signal was more intense when the proteasome redis-
fraction (Figure 2B, lanes 4±6). Perturbation of the pro-tributed to the large ataxin-1 aggregates. This redistribu-
teasome thus induces the accumulation of insoluble
tion was more evident in the b-lactone-treated popula-
forms of ataxin-1 without significantly affecting the
tion, as the larger aggregates predominated. steady-state level of soluble ataxin-1.
Proteasome Inhibition Leads to Accumulation Ataxin-1 Is Polyubiquitinated In Vivo
of Detergent-Insoluble Ataxin-1 Upon close examination of the ataxin-1 immunoreactive
We next examined whether inhibitors of the proteasome smear in Figure 2A (lanes 5 and 6), a ladder of bands
could interfere with ataxin-1 degradation. The effect of regularly spaced at intervals of z7 kDa is detectable.
b-lactone on the steady-state levels of ataxin-1 was This banding pattern indicates polyubiquitination. To
assessed by immunoblot analysis (Figure 2). HeLa cells directly test whether these ataxin-1 immunoreactive
expressing mutant ataxin-1 [92Q] were treated with ei- bands were ubiquitin conjugates, ataxin-1 [92Q] trans-
fected cells were incubated with or without b-lactone,ther different concentrations of b-lactone or dimethyl
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Figure 2. Ataxin-1 Is Polyubiquitinated In Vivo and Proteasome Inhibition Promotes Accumulation of Detergent-Insoluble Ataxin-1
HeLa cells expressing mutant ataxin-1 [92Q] were incubated with b-lactone at the concentrations indicated, and the extracts were separated
into detergent insoluble (A) and soluble fractions (B). Volumes loaded per lane represent equivalent fractions of the original cell lysate. In (A),
the same preparations loaded in lanes 1±3 were loaded with 33 volume in lanes 4±6 and immunoblotted with ataxin-1 antibody 11750. In (B),
duplicate preparations loaded in lanes 1±3 (anti-Xpress antibody) were loaded in lanes 4±6 (anti-ataxin-1 11750). While degradation of insoluble
ataxin-1 appears to be inhibited by b-lactone treatment (A), the steady-state levels of ataxin-1 in the soluble fraction appear unchanged (B).
Additionally, higher molecular weight forms of ataxin-1 (Conj.) are uniquely apparent in the insoluble fraction (A, lanes 5,6). Ataxin-1 is
polyubiquitinated in vivo (C). Insoluble His6-ataxin-1 was affinity purified in denaturing conditions from HeLa cells that were treated with
b-lactone at the concentrations indicated. Immunoblot was stained with ataxin-1 antibody 11750 (lanes 1±4, left). In (C), lanes 1 and 2 represent
lysates from mock-transfected HeLa cells and show a negligible amount of endogenous (non-His6-tagged) ataxin-1 at 1001 kDa. The blot was
then stripped and reprobed with anti-ubiquitin (lanes 1±4, right). The high molecular weight forms of ataxin-1 (lane 4, left) are immmunopositive
for ubiquitin (lane 4, right). Proteasome inhibition promotes an accumulation of both wild-type and mutant detergent±insoluble ataxin-1 (D).
HeLa cells expressing either wild-type [2Q] (lanes 1 and 2) or expanded [92Q] (lanes 3 and 4) were treated with b-lactone at the concentrations
indicated and the detergent-insoluble fractions were immunoblotted with Xpress-tag antibody.
lysed, and the detergent-soluble and insoluble fractions detergent-insoluble, nuclear matrix-associated aggre-
gates in situ (Skinner et al., 1997; Cummings et al., 1998).were subjected to denaturing His6-ataxin-1 pull-down.
Using ataxin-1 antisera, immunoblot analysis of the af- Lactacystin b-lactone also promoted the accumula-
tion of detergent-insoluble, wild-type ataxin-1 (Figurefinity-purified proteins from the detergent-soluble frac-
tions revealed no high molecular weight smear (data 2D, lanes 1 and 2). The higher levels of the mutant protein
in lanes 3 and 4 are expected, as the expanded proteinnot shown). By contrast, strong immunoreactivity was
observed as a smear of high molecular weight material tends to be more insoluble than wild-type (Figure 2D,
lanes 3 and 4). Additionally, the higher molecular weightin the lane representing the affinity-purified ataxin-1
from the detergent-insoluble fraction (Figure 2C, left lane smear was evident only when the wild-type protein was
grossly overloaded (data not shown).4). Binding of endogenous ataxin-1 that was not tagged
with His6 to the Co21 resin was negligible (left lanes
1 and 2), indicating the binding and wash conditions Mutant Ataxin-1 Is Conjugated Similarly
to the Wild-Type Protein but Is Moreemployed were stringent enough to enrich for His6-
tagged proteins. Stripping and reprobing the same blot Resistant to Degradation In Vitro
Because our tissue culture studies demonstrated ataxin-1with anti-ubiquitin (right lanes 1±4) confirms that these
high molecular weight forms of ataxin-1 are ubiquitin is ubiquitinated and is degradable by the proteasome,
we sought to develop an in vitro model to avoid someconjugates (right lane 4). Although we can not rule out
the possibility that any ubiquitinated material in the of the difficulties inherent in working with expanded
ataxin-1 in vivo (e.g., solubilization). To compare thesoluble fraction is rapidly degraded or acted upon by
deubiquitinating enzymes, it appears that the ubiquitin conjugation of ataxin-1 [2Q] and [92Q] and to evaluate
the ubiquitin-mediated degradation of the two forms ofimmunoreactivity is uniquely present in the detergent-
insoluble fractions. These results are in agreement with the protein, a cell-free system was reconstituted. While
no cell-free model could fully replicate the disease state,our previous finding that ubiquitin colocalizes with the
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mutant ataxin-1 in an ATP-dependent manner (Figure
3A). Additionally, most of the higher molecular weight
conjugates are derived from the labeled full-length pro-
teins as the lanes containing the labeled proteins incu-
bated with the ATP (1) reaction mixture show a clear
decrease in the full-length proteins (Figure 3A, arrow-
heads). Phosphoimager analysis confirmed this decrease
and further demonstrated that there is no significant
difference in the ability of the system to conjugate the
two substrates, suggesting ubiquitination of ataxin-1 is
not influenced by the polyglutamine repeat.
We next investigated the ubiquitin-mediated degrada-
tion of wild-type and mutant ataxin-1. The in vitro±
translated proteins were incubated for 3 hr with HeLa
cell extract in the absence of ubiquitin aldehyde. Follow-
ing trichloroacetic acid (TCA) precipitation, degradation
values were determined. Six independent experiments
in cell-free extract show that the ATP-mediated degra-
dation of the wild-type protein is at least three times
more efficient than that of mutant [92Q] protein (Figure
3B). Although the low values in turnover percentage
demonstrate both forms of ataxin-1 are relatively resis-
tant to proteasomal degradation in vitro, the data clearly
show that the polyglutamine-expanded protein is con-
siderably more resistant to degradation (p , 0.0005).
SCA1 Mice Lacking Ube3a Expression Have Fewer
Nuclear Aggregates
To evaluate the possible role of the ubiquitin pathway
in SCA1, we crossbred B05 mice with the well-character-
ized animals lacking Ube3a expression. In these experi-
ments, we took advantage of the imprinted expression
pattern for Ube3a (preferential silencing of the paternal
allele in Purkinje cells). Matings were designed to yield
SCA1 mice with a targeted disruption of the maternal
Ube3a allele (maternal deficiency for Ube3a(m2/p1)). MaleFigure 3. Polyubiquination and Degradation In Vitro
heterozygous B05 transgenic mice were mated with fe-Wild-type and mutant ataxin-1 show similar ATP-dependent ubiqui-
male heterozygous Ube3a mice, which produced litterstin conjugation in vitro (A). Lanes 1±3: 35S-ataxin-1 [2Q] and lanes
with the expected ratios for each genotype. As antici-4±6: 35S-ataxin-1 [92Q]. Conjugation (Conj.) occurs only when the
proteins are allowed to incubate in the reaction mixture containing pated, the B05, Ube3a(m2/p1), and B05/Ube3a(m2/p1) mice
ATP. Phosphoimager analysis reveals no difference in the amount developed normally and were indistinguishable from
of conjugation between the two substrates. Arrowheads indicate each other and wild-type littermates by cage behavior
where the full-length protein migrates. Mutant ataxin-1 is more resis-
for the first 3 months. As controls, B05 animals with atant than wild-type to ATP-dependent degradation in vitro (B). An
paternal deficiency were also established (see below).average of six independent experiments in cell-free extract shows
The mechanism involved in NI formation and the roleataxin-1 [2Q] and [92Q] are relatively stable in cell-free extract minus
ATP (4.2% versus 4.7% degraded, respectively). When ATP is in- the inclusions play in SCA1 pathogenesis are unclear.
cluded in the reaction mixture, there is a 7.6 net change in the The NIs in B05 transgenic mice are first evident at 3.5
degradation of ataxin-1 [2Q] (11.8% degraded with ATP). Mutant weeks by immunohistochemistry using either anti-
ataxin-1 [92Q], however, has only a 2.5 net change in degradation
ataxin-1 or anti-ubiquitin antisera (C. J. C., unpublishedwhen ATP is included in the reaction mixture (7.2% degraded with
observation). The fraction of Purkinje cells with NI in-ATP). Therefore, polyglutamine-expanded ataxin-1 is degraded 33
creases with age until 12 weeks, when approximatelyless efficiently than nonexpanded ataxin-1 in vitro (p , 0.0005).
90% of these neurons contain NI as determined by im-
munofluorescence confocal microscopy (Skinner et al.,
1997). To asses the role of E6-AP in NI formation, wethe goal was to gain insight into the biochemical proper-
ties of mutant ataxin-1. For conjugation, ataxin-1 [2Q] analyzed the subcellular localization of ataxin-1 in cere-
bellar sections from the Ube3a, the B05, and the B05/and [92Q] were translated in the presence of 35S-methio-
nine from their respective cDNAs using wheat germ± Ube3a double-mutant mice at 6.5, 9.5, and 12.5 weeks.
By immunohistochemistry, the distribution of endoge-coupled transcription-translation extract. The in vitro
translated proteins were then incubated with a reaction nous ataxin-1 in the Ube3a(m2/p1) cerebellum was similar
to wild-type (data not shown). In Purkinje cells from 9.5-mixture containing the necessary components for ubi-
quitin conjugation including HeLa cell extract, ATP, week-old B05 mice, ataxin-1 is primarily concentrated to
a single nuclear structure, with some sparse distributionand ubiquitin. This reconstituted cell-free system was
sufficient to support conjugation of both wild-type and throughout the nucleus (Figures 4A, 4C, 4E, and 4G). In
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Figure 4. Altered Ataxin-1 Distribution in B05/Ube3a(m2/p1)
Ataxin-1 immunostaining demonstrates that B05 mice lacking expression of Ube3a have a more diffuse nuclear distribution of ataxin-1 as
well as a reduced frequency of NI compared to B05 littermates. Cerebella from B05 transgenic animals (A, C, E, and G) and B05/Ube3a(m2/p1)
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Ube3a(m2/p1) mice had a 4- to 5-fold reduction in percent-
age of NI at 6.5 and 9.5 weeks compared to B05 lit-
termates. It is intriguing to note that the NI percentage
increased with time: there was a 3-fold difference in NI
percentage at 12.5 weeks. These data suggest that the
lack of this E3-ubiquitin ligase causes a delay in the
appearance of NIs, but that other factors are contribut-
ing to their formation. Immunohistochemical analysis
using ubiquitin antibody demonstrated that the NI that
eventually forms in the Purkinje cells in the double-
mutant animals contained ubiquitinated material (Figure
4H). Northern blot analysis demonstrated no change
in SCA1 transgene expression in the B05/Ube3a(m2/p1)
animals, confirming that the decreased frequency of the
NI formation was not due to alterations in transgene
expression (data not shown). Furthermore, these changes
are not due to genetic background effects, as the per-
centage of Purkinje cells at 9.5 weeks in B05 mice with
a paternal deficiency for Ube3a(m1/p2) is comparable to
that of the B05 littermates containing two wild-type
Figure 5. B05 Mice Lacking Expression of Ube3a Have Reduced Ube3a(m1/p1) alleles (51% in B05 versus 52% in paternally
Frequency of Nuclear Aggregates
deficient). In addition, examination of animals at 12.5
The bars represent the percentage of Purkinje cells with nuclear weeks while blinded to which parent provided the null
aggregates at 6.5, 9.5, and 12.5 weeks. The data were generated
allele revealed two levels of aggregate frequency at thefrom more than three different animals at each age and the total
expected 3-fold difference, e.g., 14% versus 47% Pur-number of Purkinje cells used to calculate the frequency of aggre-
kinje cells with nuclear aggregates.gates is as follows: n 5 2893, 4255, and 1825 for B05 at 6.5, 9.5,
and 12.5 weeks, respectively, and n 5 3429, 2538, 1647 for B05/
Ube3a(m2/p1) at 6.5, 9.5 and 12.5 weeks, respectively (means and SCA1 Mice Lacking Ube3a Expression Have Severe
SEM are shown). A significant decrease in aggregate frequency is SCA1 Pathology
noted in cerebella from B05 animals lacking expression of Ube3a
Because the frequency of the nuclear inclusion forma-(*p , 0.0001).
tion was reduced in the double-mutant mice, it was of
particular interest to compare cerebellar sections from
contrast, Purkinje cells from age-matched littermate B05 the B05 mice with and without expression of Ube3a to
animals lacking expression of Ube3a(m2/p1) showed pre- determine if any of the cellular abnormalities observed
dominantly a diffuse nuclear distribution for ataxin-1 in the B05 mice were affected (Burright et al., 1995;
with a small number of nuclei containing micropunctate Clark et al., 1997). Upon analysis of the NI frequency, it
structures or a single NI (Figures 4B, 4D, 4F, and 4H). became clear that the B05 cerebellar pathology was
Additionally, by visual observation of many sections, the greatly accelerated in the B05/Ube3a(m2/p1) mice. This
diffuse ataxin-1 staining appears more intense in the included an advanced thinning of the molecular layer
double-mutant Purkinje cells compared to the B05 lit- and displaced Purkinje cells. To better compare the
termates (Figures 4B, 4D, and 4F). This may be due to pathological changes in the two sets of animals, cerebel-
either a higher level of total protein in the nucleus or to lar morphology was analyzed using anti-calbindin im-
the fact that it is not sequestered to an NI. munofluoresence. Figures 6A and 6B show the normal
The percentage of Purkinje cells with nuclear aggre- cerebellar morphology of 20-week-old wild-type and
gates was determined by dividing the number of Purkinje Ube3a(m2/p1) mice, respectively, demonstrating that there
cells with aggregates by the total number of Purkinje are no detectable alterations in the Ube3a-deficient
cells counted in the entire midsagittal cerebellar hemi- mice. As previously reported (Clark et al., 1997), the B05
sphere 5 mm section. Although confocal z-scan analysis mice show an early pattern of Purkinje cell pathology
yields a greater proportion of neurons with NI (Skinner that includes the appearance of cytoplasmic vacuoles
et al., 1997), we chose to count Purkinje cells following and a thinning of Purkinje cell dendritic arborization (Fig-
standard immunohistochemistry and hematoxylin coun- ures 4E and 6C). In B05/Ube3a(m2/p1) age-matched lit-
terstain, as it allowed for a greater number of Purkinje termates (9.5 weeks), however, the thinning of the mo-
cells to be analyzed ($16,500 cells total). The frequency lecular layer, loss of Purkinje cell dendritic arborization,
of NI in B05 Purkinje cells increased with age from 35% and Purkinje cell heterotopia are much more pro-
nounced (Figure 6D). In fact, Purkinje cell displacementat 6.5 weeks to 61% at 12.5 weeks (Figure 5). The B05/
littermates at 9.5 weeks (B, D, F, and H). Sections were stained with anti-ataxin-1 11NQ in (A)±(F) and anti-ubiquitin in (G) and (H). Immunofluores-
cence confocal microscopy shows sparse nuclear staining with a concentration of ataxin-1 to the NI in B05 Purkinje cells (A). In contrast,
ataxin-1 immunoreactivity is much more diffuse throughout the nucleus in Purkinje cells in the B05 animals lacking Ube3a (B). Scale bar is
in micrometers. The reduced frequency of nuclear aggregates is readily seen with low magnification of the cerebella. Arrows point to Purkinje
cells with NI in (C) and arrowhead points to cytoplasmic vacuole in (E). High magnifications of boxed regions in (C) and (D) are shown in (E)
and (F) respectively. Arrows in (F) show diffuse staining of ataxin-1 with occasional small punctate aggregates. As previously reported, the
NI in B05 transgenic mice contain ubiquitin (G). The small aggregates that occasionally form in B05/Ube3a (m2/p1) Purkinje cells contain ubiquitin
(shown by arrows in H).
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Figure 6. Immunofluorescence Confocal Microscopy of B05/Ube3a(m2/p1) Shows Altered Cerebellar Morphology
Staining was performed using antisera against the Purkinje cell±specific protein, calbindin.
(A) Cerebellar section from a 20-week-old wild-type mouse.
(B) Cerebellar section from a 20-week-old Ube3a(m2/p1) littermate mouse showing Purkinje cell morphology identical to that of the 20-week-
old wild-type mouse.
(C) Cerebellar section from a 9.5-week-old B05 mouse demonstrating early alterations in Purkinje cells morphology, including thinning of the
dendritic arborization.
(D) Cerebellar section from a 9.5-week-old B05/Ube3a(m2/p1) showing extensive loss of Purkinje cell dendritic arborization, a shrinkage of the
molecular layer (ml), disorganization of the Purkinje cell layer (pcl), and numerous heterotopic Purkinje cells (arrowheads). Except for mild
loss in the dendritic tree, none of these changes are evident in B05 littermates. Scale bar is in micrometers.
into the molecular layer is not evident in the B05 mice (data not shown). These results indicate that lack of ex-
pression of an E3-ubiquitin ligase accelerates the poly-until ages beyond 12 weeks.
glutamine-induced pathology in the SCA1-transgenicWe next evaluated the progression of pathology in
animals. Moreover, this pathology is not dependent onthe double mutant animals at 9.5, 12.5, and 14.5 weeks
NI formation.using antibodies to ataxin-1 (11NQ) and calbindin (Fig-
ures 7D±7F, respectively). While the subcellular localiza-
tion of ataxin-1 was primarily nuclear and concentrated Discussion
to the NI in the B05 mice at 14.5 and 35 weeks (Figures
7B and 7C, respectively), the distribution of ataxin-1 was The ubiquitin-proteasome system is an elaborate mech-
much more diffuse in the nucleus with limited staining anism that cells have developed to regulate the activities
in the cytoplasm in the double-mutant animals (Figures of normal proteins as well as to avoid the potentially
7D±7F). More striking, however, is the radical loss of toxic effects of mutant or misfolded proteins. Given the
dendritic arborization, vacuolation, and severe Purkinje significance of proper protein turnover, it is not surpris-
cell heterotopia in sections from the B05 transgenic mice ing that perturbations in the system have been impli-
lacking Ube3a(m2/p1) expression. The impressive alter- cated in the pathogenesis of a number of diseases (Cie-
ations in Purkinje cell morphology that develop in the chanover, 1998; Mayer et al., 1998; Schwartz and
double-mutant mice at 14.5 weeks (Figure 7F) are com- Ciechanover, 1999). We have used cell-free, cell culture,
parable to those of B05 mice at ages greater than 9 and animal models to investigate the significance of the
months (Figure 7C). As a control, we examined a B05 ubiquitin-proteasome pathway in the pathogenesis of
mouse with a paternal deficiency for Ube3a(m1/p2) at 9.5 SCA1.
weeks. The mouse showed Purkinje cell morphology and Several lines of evidence demonstrate that ataxin-1 is
ataxin-1 distribution that was similar to B05 age-matched ubiquitinated and degraded by the ubiquitin-dependent
proteasome complex. First, inhibitors of the proteasomelittermates containing two wild-type Ube3a(m1/p1) alleles
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Figure 7. The B05 Mice with a Deficiency in Ube3a(m2/p1) Show Accelerated SCA1 Pathology
Immunofluorescence confocal microscopy was performed with antisera against calbindin (red) and ataxin-1 (green 5 yellow in merged image)
(A) 12.5-week-old Ube3a(m2/p1) mouse with normal Purkinje cell morphology (calbindin signal alone).
(B) 14.5-week-old B05 transgenic mouse showing cytoplasmic vacuoles (arrow), reduction in the dendritic arborization, and subtle disruption
in the Purkinje cell layer, including heterotopic Purkinje cells in the molecular layer. Ataxin-1 staining is concentrated to the NI with moderate
diffuse nuclear staining.
(C) 35-week-old B05 transgenic animal with Purkinje cell loss and increased severity of changes described in (B). In addition, ataxin-1 staining
is now predominantly limited to the nuclear inclusion.
(D) 9.5-week-old B05/Ube3a(m2/p1) mouse with accelerated pathology compared to a 14.5-week-old B05 animal (described in B). Arrow points
to Purkinje cell with cytoplasmic vacuole. Arrowheads indicate Purkinje cells displaced deep into the thinning molecular layer. Ataxin-1 staining
is predominantly diffuse throughout the nucleus. Nuclear inclusions are rare.
(E) 12.5-week-old B05/Ube3a(m2/p1) mouse has severe cerebellar pathology with numerous heterotopic Purkinje cells in the molecular layer.
These animals show severe dendritic pathology. As in (D), nuclear inclusions are infrequent.
(F) 14.5-week-old B05/Ube3a(m2/p1) mouse has severe dendritic pathology, Purkinje cell heterotopia, and significant Purkinje cell loss. The
cerebellar changes are comparable to B05 mice at greater than 9 months, yet nuclear inclusion frequency is much reduced. Moreover, the
staining pattern for ataxin-1 is diffuse/punctate throughout the nucleus and occasionally in the cytoplasm.
Scale bar is in micrometers.
increased the frequency of ubiquitin-positive nuclear proteolytic inhibition caused by a repeat in the target
substrate. The Epstein-Barr nuclear antigen 1 (EBNA-1)aggregates in transfected cells. The proteasome inhibi-
tor, b-lactone, also interfered with ataxin-1 degradation, has evolved to resist MHC class I±restricted presenta-
tion by a long polymorphic Gly-Ala repeat that wasleading to an accumulation of insoluble, high molecular
weight polyubiquitinated forms of ataxin-1. In a cell- shown to inhibit its ubiquitin-dependent degradation by
the proteasome (Levitskaya et al., 1997). The repeatfree reconstituted system, we demonstrated the ATP-
dependent polyubiquination of both wild-type and ex- itself was later shown to confer protection from protea-
somal degradation when inserted into IkBa (Sharipo etpanded forms of ataxin-1 and showed both substrates
were equally well conjugated. al., 1998). Could the polyglutamine repeat act in a similar
manner, impeding proteasomal degradation of ataxin-1?While ubiquitination directs the degradation of ataxin-1,
the defect leading to the accumulation of the mutant The present study supports this notion. In vitro wild-
type ataxin-1 [2Q] was degraded 33 more efficientlyprotein in NIs is, however, less clear. Conjugation of
wild-type and mutant ataxin-1 occurs equally well in than mutant ataxin-1 with 92 glutamines. This altered
catabolism seen in vitro may have biological relevancevitro, suggesting the limiting factor in clearance of mu-
tant ataxin-1 is not the conjugation of ubiquitin but rather toward understanding the slow progressive nature of
the human disease (see below). A long polyglutaminethe recognition or hydrolysis of the mutant protein by the
proteasome. There is at least one example of selective tract has several properties that could render a protein
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with an expanded repeat more resistant to degradation. The polyglutamine-induced pathology in the SCA1
Perutz et al. (1999) have proposed that expansion of the transgenic mice is characterized by cytoplasmic vacu-
polyglutamine repeat beyond a critical threshold could oles, progressive loss of dendritic arborization, and
generate stable hydrogen-bonded hairpins that may as- Purkinje cell heterotopia (Clark et al., 1997). The com-
sociate to form b sheet structures. The polyglutamine bination of cytoplasmic vacuoles and Purkinje cell
repeat likely causes expanded ataxin-1 to adopt a spec- heterotopia is unique and has not been described for
trum of abnormal protein conformations, some of which any other mouse model (genetic, acquired, or induced)
may be energetically more stable than the native confor- (Norman et al., 1995; Luo et al., 1996; Mourre et al.,
mation, thus impeding its unfolding and subsequent hy- 1997). Thorough histopathological examination of Ube3a-
drolysis. Also consistent with this model are recent find- deficient mice revealed normal histology of the brain
ings that the levels of ataxin-2 in affected neurons in (Jiang et al., 1998). We therefore conclude that the se-
SCA2 brain tissue are higher than normal brain tissue vere, progressive pathological changes in the SCA1
despite the absence of intranuclear ubiquitinated inclu- transgenic mice lacking expression of Ube3a is caused
sions (Huynh et al., 1999). by the toxic effect of mutant ataxin-1 aggravated by the
That inhibition of the proteasome led to an increase in lack of E6-AP function. Moreover, the severe pathology
size and frequency of aggregates in HeLa cells suggests is very similar to that seen in the cerebellum of late-
that the proteasome suppresses NI formation by clear- stage SCA1 transgenic animals, suggesting that lack
ing misfolded proteins. A similar finding was recently of E6-AP accelerates the polyglutamine-induced phe-
reported by Chai et al., who demonstrated that protea- notype.
some inhibition increased ataxin-3 aggregation (Chai et There could be many explanations for how the lack
al., 1999). These findings suggest the role of the ubiqui- of E6-AP contributes to the toxicity caused by mutant
tin-proteasome pathway in neurodegeneration is not ataxin-1. The most ready explanation is that E6-AP sub-
limited to SCA1 and may, in fact, extend to other neuro- strate(s) is not being properly conjugated and degraded.
degenerative diseases. Studies in a German family with Assuming ataxin-1 is an E6-AP substrate, loss of this
Parkinson's disease have revealed that a missense muta- E3 activity could result in altered ataxin-1 ubiquitination
tion in the ubiquitin carboxy-terminal hydrolase gene and hydrolysis. Elevated levels of ataxin-1 could, in turn,
(UCHL1) causes a partial loss of the catalytic activity of correspond to gain of ataxin-1 function, either intrinsic
this protease. Such an aberration is thought to alter the or acquired. Several mouse models of polyglutamine
cellular ubiquitin pools, which could lead to perturba- repeat diseases have shown that it is necessary to over-
tions of the proteolytic pathway and aggregation of pro- express the full-length mutant protein in order to mani-
teins destined for hydrolysis (Leroy et al., 1998). More fest symptoms that parallel the human disease (Burright
recently, an intragenic deletion in the mouse ubiquitin et al., 1995; Reddy et al., 1998). A system can be defined
hydrolase gene was demonstrated to be responsible by both its input and turnover, so it is not unreasonable
for gracile axonal dystrophy (gad) (Saigoh et al., 1999). to propose that some of the SCA1-like phenotypes in
These mice have features characteristic of many human the B05 mice appear because of elevated levels of the
inherited neurodegenerative disorders, including sen- mutant protein due to transgene overexpression. One
sory and motor ataxia, ubiquitin-positive deposits, and interpretation of the data presented here is that it is
specific neuronal degeneration. possible to accelerate the polyglutamine-induced phe-
Cell-specific factors that alter protein turnover may notype by manipulating the other end of the system,
help explain the selective neuronal degeneration seen in i.e., obstructing the ubiquitination of the mutant protein.
polyglutamine disease. The degeneration of only certain Along the same lines, it may now be possible to acceler-
cell types, which differ from one disease to the next, is ate a phenotype in the short life span of otherwise unaf-
puzzling given that the relevant proteins are ubiquitously fected transgenic or knockin models that express low
expressed. One hypothesis put forth to explain the issue
levels of the mutant transgene.
of selective neuronal degeneration in polyglutamine dis-
Establishing whether or not ataxin-1 is a substrate for
eases proposes that mutant ataxin-1 might interact with
E6-AP could, however, be an arduous task. Although weprotein(s) that is more abundantly expressed or are es-
have demonstrated the cell-free reconstituted system issential in the vulnerable neurons. The leucine-rich acidic
sufficient for ataxin-1 ubiquitination, we were unable tonuclear protein (LANP) is a candidate to mediate SCA1
demonstrate specific E6-AP-dependent ubiquitinationpathogenesis based on its interactions with mutant
of ataxin-1 in vitro (data not shown). These experimentsataxin-1 and its expression and subcellular distribution
do not formally exclude the possibility that ataxin-1 ispatterns (Matilla et al., 1997). Selective degeneration
a substrate for E6-AP in vivo. The mechanisms underly-could also be determined by cell-specific factors that
ing the high specificity and selectivity of E3-mediatedinfluence the folding and/or turnover of mutant ataxin-1.
conjugation are as yet unresolved (Patton et al., 1998).E6-AP might be a good candidate, given its role in defin-
In fact, many signals may be involved prior to recognitioning substrate specificity in the UPP, its limited expres-
by the appropriate E3-ligase, including posttranslationalsion pattern in the CNS, and its functional importance
modification and/or association with ancillary proteinsin Purkinje cells as evidenced by the ataxia phenotype
such as molecular chaperones (Patton et al., 1998; Koeglin AS. Moreover, there are interesting similarities be-
et al., 1999). If it can be established that ataxin-1 is atween the results presented here and the identification
substrate for E6-AP, it will be interesting to define theof huntingtin and atrophin-1 interactors that are specu-
particular pathway involved in its catabolism and deter-lated to be responsible for the targeted ubiquitination
mine if this pathway is involved in the degradation ofand catabolism of the HD and DRPLA gene products
(Kalchman et al., 1996; Wood et al., 1998). other polyglutamine repeat proteins.
Accelerated Pathology in Ube3a-Deficient SCA1 Mice
889
The accelerated phenotype in the double-mutant ani- transgenic mice ataxin-1 localized predominantly to nu-
clear aggregates, with limited diffuse nuclear localiza-mals could, alternatively, be the result of altered turnover
of other E6-AP-specific targets. If the levels of these tion. In the B05 transgenic animals lacking Ube3a ex-
pression, however, ataxin-1 was diffused throughout thefactors changed in the cellular pool, there could be an
indirect effect on the polyglutamine-induced degenera- Purkinje cell nucleus and cytoplasm, and found only
infrequently in nuclear aggregates. One possible expla-tive pathway. We would then need a better understand-
ing of the pathway leading to neurodegeneration and nation of this accelerated phenotype is that mutant
ataxin-1 is more toxic if not properly ubiquitinated,the role these factors might play in SCA1 pathogenesis.
Whether the pathological alterations in the double mu- turned-over, or sequestered to an NI, especially if the
capacity of the proteasome system is exceeded. Ideallytants are directly or indirectly associated with mutant
ataxin-1 toxicity, we have shown that perturbing this this hypothesis would be well supported by analysis of
the relative half-life of mutant ataxin-1 in the B05 andpathway accelerates the SCA1-like phenotype in mice.
The significance of this pathway in the SCA1 phenotype B05/Ube3a(m2/p1) mice. Although immunohistochemistry
analysis suggests that the level of ataxin-1 is higher incould be further elucidated by generating transgenic
animals that overexpress Ube3a in Purkinje cells and the double-mutant animals (Figure 4), it remains techni-
cally challenging to quantitate the abundance of mutantthen crossing these animals with the SCA1 mice.
The reduced frequency of mutant ataxin-1 aggrega- ataxin-1 in the two animals given that the protein is
extremely refractory to solubilization and extractiontion in animals deficient for E6-AP demonstrates that
other factors, in addition to the polyglutamine repeat, (Burright et al., 1995).
Whether the aggregates themselves are toxic or pro-influence NI formation. The conjugation of multiple ubi-
quitin moieties to a protein, which already has a native tective, the data presented here suggest that merely
delaying or inhibiting the aggregation of mutant ataxin-1conformation destabilized by a polyglutamine tract,
could conceivably contribute to its misfolding and ag- will not prevent disease. An effective therapy may re-
quire preventing protein aggregation while at the samegregation. The increased frequency of ubiquitin-positive
NIs over time clearly suggests that there are other fac- time enhancing proteolysis of the mutant form of the
protein. Molecular chaperones are known to work intors involved (e.g., other E3-ligases). Although the steps
leading to NI formation are not yet clear, several obser- concert with the proteasome, recognizing, unfolding,
and presenting misfolded proteins for hydrolysis. A bet-vations indicate the ubiquitin pathway may be involved.
First, ubiquitin is one of the first epitopes to be recog- ter understanding of the mechanisms that underlie the
high selectivity of the ubiquitin-proteasome pathway asnized in the developing NI in SCA1-transgenic mice.
Second, the ubiquitinated forms of ataxin-1, in HeLa well as the signals involved in the target ubiquitination
of ataxin-1 will be important for therapeutic intervention.cells, are uniquely found in the detergent-insoluble frac-
tion. Third, preventing turnover of the ubiquitinated
forms of ataxin-1 with proteasome inhibitors leads to
Experimental Proceduresincreased ataxin-1 aggregation. Fourth, the frequency
of NI in SCA1-transgenic animals is diminished by the
Plasmidsabsence of an E3-ubiquitin ligase. Furthermore, Saudou
SCA1-expression vectors were previously described (Cummings et
et al. have recently demonstrated that the ubiquitination al., 1998). To generate a human SCA1 cDNA containing 2 CAG
of mutant huntingtin may be important for nuclear aggre- repeats, two sets of primers were used to amplify the 59 and 39
ends of the region flanking the CAG repeat (primers 59 to 39:(1)gate formation by demonstrating that the expression
ccgtcaccagtgcagtggcc; (2) tgctgctgctcagccttgtgtcccggcgt; (3) ag-of a dominant-negative ubiquitin-conjugating enzyme
cagcagcacctcagcagggctccg; (4) tgaggaaccgacttgccgc). The 59 am-inhibited the formation of intranuclear inclusions (Sau-
plified product and the 39 amplified product were used as templatesdou et al., 1998).
in a subsequent reaction with the outside set of primers. The reaction
It has been proposed that the neuronal inclusions are product was SfiI digested and subcloned into the pcDNA-ataxin-1
the common, underlying cause of all diseases due to vector (Cummings et al., 1998). SCA1 [2Q and 92Q] cDNAs were
also subcloned into the EcoR1-XhoI sites in pZErO-2 (Invitrogen)glutamine repeat expansions (Alves-Rodrigues et al.,
for SP6-mediated in vitro transcription.1998; Perutz, 1999). Not all polyglutamine diseases,
however, are associated with NI (Huynh et al., 1999).
More importantly, Klement et al. demonstrated that mice
Cell Culture and Proteasome Inhibitor Treatment
expressing mutant ataxin-1 (77Q) lacking the self-asso- Transient expression of ataxin-1 in HeLa cells was performed as
ciation regionÐwhich is essential for ataxin-1 dimeriza- previously described (Cummings et al., 1998). Cells were treated
(24 hr posttransfection) for 8 hr with 20 mM clasto-LactacystintionÐdevelop ataxia and Purkinje cell pathology similar
b-Lactone (Calbiochem) or 50 mM MG132 (Affiniti Research) into the B05 mice, but without apparent ataxin-1 aggrega-
DMSO. Control cells were treated equally with DMSO carrier alonetion (Klement et al., 1998). The present studies, per-
(when noted). For analysis of GFP-ataxin-1, cells were washed twice
formed with mice expressing the full-length mutant pro- in PBS and fixed at 48C for 30 min in 3.7% formaldehyde and
tein lead us to the same conclusion made by Klement mounted (Vectashield, Vector Laboratories). Multiple random fields
et al.: NIs do not initiate SCA1 pathogenesis in mice. were counted for the presence of nuclear aggregates while the
investigator was blind to the treatment protocol. Experiments wereSCA1 transgenic mice lacking expression of the Ube3a
performed twice (.500 cells counted/experiment).have accelerated pathology with reduced frequency of
To analyze ataxin-1 aggregation and proteasome distribution,NI formation. NI formation clearly does not correlate
transfected and inhibitor-treated cells (as above) were stained ac-
with disease in this model. In fact, the formation of the cording to Cummings et al., 1998. Xpress-epitope antibody (In-
NI may initially sequester the toxic protein, thereby pro- vitrogen) and rabbit polyclonal antibody to the 20S proteasome
(Affiniti Research) were diluted 1:500.tecting the nucleus from its toxic effects. In the B05
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Immunoblotting and Cell Fractionation Mouse Breeding and Purkinje Cell Counting
To generate B05 mice maternally deficient for Ube3a, femaleTransfected HeLa cells were isolated and counted. Proteasome in-
hibitor treatment was performed as described above. Cell equiva- Ube3a(2/1) mice on a mixed background (C57BL/6 and 129/SvEv)
were mated with male B05(2/1) mice (FVB/N). As controls, the reverselents were pelleted at 228 3 g and lysed in 500 ml lysis buffer: 10
mM Tris-HCL, pH 8.0, 1% Triton X-100 and 53 protease inhibitors was performed to generate B05 mice paternally deficient for Ube3a.
The frequency of Purkinje cells with nuclear aggregates was deter-(Complete, Boehringer Mannheim) for 30 min on ice. The insoluble
material was collected by centrifugation 13,000 3 g for 15 min at mined following staining with anti-ataxin-1 11NQ (Skinner et al.,
1997) on cerebella from B05 and B05/Ube3a(m2/p1) littermates. For48C and solubilized in 23 SDS sample buffer. DNA was sheared by
passage through 22G needle. Western analysis was according to each time point, 3±6 brains (multiple sections/brain) were used for
each genotype. Greater than 16,500 Purkinje cells were counted inSkinner et al., 1997. Anti-ataxin-1 11750 was diluted 1:5000 and
monoclonal anti-Xpress diluted 1:1000. total (see Figure 5). A Purkinje cell with any size aggregate was
scored as a positive (633 objective). Mean, SEM, and t test (two
sample assuming unequal variances) were determined in MicrosoftMetal Affinity Protein Purification
Excel. As a control, we examined a B05 mouse paternally deficientCells were transfected, treated with proteasome inhibitor, and
for Ube3a(m1/p2) and found it to have a similar frequency of Purkinjecounted as described above. Insoluble material was solubilized by
cells with nuclear aggregates compared to B05 littermates at 9.5vortexing in 500 ml Guanidinium buffer: 50 mM NaH2PO4 (pH 8.0),
weeks (number of Purkinje cells counted for B05, n 5 1, 788; for10 mM Tris-HCl (pH 8.0), 6 M Guanidinium2HCl, 100 mM NaCl. DNA
B05/Ube3a(m1/p2), n 5 912).was sheared by brief sonication. Any nonsolubilized material was
cleared by 15 min centrifugation at 13,000 3 g at 48C. The superna-
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